Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US44486Q1031
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00XPPT7S7
HUMA
Humacyte Inc
GICS: Financials · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $BANK
NAME
Humacyte Inc
ISIN
US44486Q1031
TICKER
HUMA
MIC
XNAS
REUTERS
HUMA.OQ
BLOOMBERG
HUMA US
Mo., 06.01.2025       Humacyte
US44486Q1031

LOS ANGELES, Jan. 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ: HUMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. S...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 06.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to cont...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 03.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 3, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 03.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to r...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 02.01.2025       Humacyte
US44486Q1031

LOS ANGELES, Jan. 2, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA)....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 02.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 2, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to cont...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 02.01.2025       Humacyte
US44486Q1031

LOS ANGELES, Jan. 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Humacyte, Inc. ("HUMA" or "the Company") (NASDAQ: HUMA) for violations of the federal securities laws. Shareholders who...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 02.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encou...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 02.01.2025       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi &...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 31.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 31, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 31.12.2024       Humacyte
US44486Q1031

The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Middle District of North Carolina on behalf of those who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ:HUMA) securities between May 10, 2024, through October 17, 2024 (“the Class Period”). Investors ha...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 31.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 31, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 30.12.2024       Humacyte
US44486Q1031

LOS ANGELES, Dec. 30, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA)....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 30.12.2024       Humacyte
US44486Q1031

LOS ANGELES, Dec. 30, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ: HUMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 30.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to con...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
So., 29.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 28, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Sa., 28.12.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Fa...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 27.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 27, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 27.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are enco...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 27.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 27, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 26.12.2024       Humacyte
US44486Q1031

BENSALEM, Pa., Dec. 26, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Class Period: May 10, 2024 – October 17, 2024 Lead Plaintiff Deadline: January 17, 202...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 26.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to con...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 26.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 25, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mi., 25.12.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Fa...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 24.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 24, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 23.12.2024       Humacyte
US44486Q1031

LOS ANGELES, Dec. 23, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ: HUMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 23.12.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Fa...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 23.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to con...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 23.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 22, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purchased...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
So., 22.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 21, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 20.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 20.12.2024       Humacyte
US44486Q1031

– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair –...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 19.12.2024       Humacyte
US44486Q1031

LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA)....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 19.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 18, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 19.12.2024       Humacyte
US44486Q1031

San Francisco, California--(Newsfile Corp. - December 18, 2024) - Humacyte insiders recently offloaded a significant portion of company stock, raising eyebrows amidst a brewing legal storm. According to recent SEC filings, Ayabudge LLC, an entity controlled by Board member Brady W. Dougan, who is married to CEO and President Laura Niklason, dispose...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mi., 18.12.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi &...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 17.12.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Fa...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 17.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 17, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 17.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 16, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 17.12.2024       Humacyte
US44486Q1031

LOS ANGELES, Dec. 16, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA)....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 16.12.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Fa...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 16.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 16, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to con...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 16.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 15, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purchased...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
So., 15.12.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Fa...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
So., 15.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 14, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Sa., 14.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 13, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Sa., 14.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 13, 2024) - The law firm of Kirby McInerney LLP reminds investors of the January 17, 2025, deadline to seek the role of lead plaintiff in a federal securities class action that has been filed on behalf of those who acquired Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA) securities during t...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 13.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 13, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 13.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 13, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 13.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 12, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink